Equillium Inc.

EQ | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.83

-$0.06 (-3.43%)

Sep 22, 2026, 2:31 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.43%

(1D)

Rating

Updated: Sep 4, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $116.02M

1D Range

1.82 1.94

52W Range

0.76 3.54

Valuation (TTM)

PE -7.31

PB 2.14

EV/EBITDA -3.44

Valuation (NTM)

Forward PE N/A

Forward PEG -0.63

Price Target $6.25

Cash Flow

FCF Yield -16.8%

SBC Adj. FCF Yield -19.4%

SBC Impact -15.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -108.0% | -9.3%

Dil EPS 3Y | 5Y -2.8% | 59.8%

FCF 3Y | 5Y -11.2% | 9.6%

Returns

ROA -30.7%

ROE -41.1%

ROIC -34.1%

Financial Health

Net Cash

$56.58M

Current Ratio 23.40

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorde...

Sector Healthcare

Industry Biotechnology

Employees 14

IPO Date Oct 11, 2018

Website equilliumbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$6.50

Upside

+255.19%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞